<DOC>
	<DOCNO>NCT02303444</DOCNO>
	<brief_summary>The purpose study ass use Multikinase Inhibitors ( MKIs ) treatment patient progressive differentiate thyroid carcinoma ( DTC ) refractory radioactive iodine ( RAI ) symptom .</brief_summary>
	<brief_title>An Observational Study Differentiated Thyroid Cancer Which Radioactive Iodine ( RAI ) Refractory Assess Use Multikinase Inhibitors</brief_title>
	<detailed_description>The primary objective study compare time symptomatic progression ( TTSP ) study entry asymptomatic patient RAI-refractory progressive DTC decision initiate MKIs study entry asymptomatic patient RAI-refractory progressive DTC decision initiate MKIs study entry .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Histologically/cytologically document DTC ( papillary , follicular , Hurthle cell , poorly differentiate carcinoma ) DTC refractory RAI Radiological progression preferably accord RECIST 1.1 No symptom due DTC &gt; /=1cm diameter lesion confirm radiological exam Life expectancy least 6 month Plan treat accord clinical trial protocol intervention include locoregional therapy systemic therapy Previous treatment MKIs advance disease Hospice patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Progressive radioactive iodine refractory differentiate thyroid carcinoma</keyword>
</DOC>